Diclomec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diclomec

Property Description
Active ingredient Diclofenac (Sodium or Potassium salt)
Form Tablet, Capsule, Solution for Injection, Topical Gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

What is Diclomec and Its Pharmacological Classification?

Diclomec is a medicinal preparation centered on the active substance Diclofenac, which is globally recognized and officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is a synthetic compound, chemically structured as a phenylacetic acid derivative. This pharmacological class designation signifies that the drug actively targets the underlying mechanisms of pain and inflammation, providing relief without utilizing narcotics or corticosteroids.

The Active Ingredient: Composition and Available Forms

The composition of Diclomec relies on Diclofenac as the single active ingredient, typically synthesized as either the sodium or potassium salt to ensure optimal absorption in the body. It is manufactured as a versatile, single-ingredient product available across multiple dosage forms, including oral solid tablets, parenteral preparations such as a solution for injection, and topical preparations like a topical gel. This range of options allows for both systemic and targeted local routes of administration.

What is the General Purpose of Diclomec?

The general purpose of Diclomec is to exert its core analgesic, anti-inflammatory, and antipyretic effects. Its utility is clinically recognized for managing general discomfort associated with conditions that involve swelling and tenderness. The drug functions by inhibiting the synthesis of prostaglandins, which are the chemical messengers responsible for initiating pain, inflammation, and fever. This intervention provides relief by directly addressing the biochemical source of the discomfort, thus establishing the medicine as a proven pharmaceutical tool for overall pain and inflammation reduction.

Regulatory References

  1. Diclofenac Oral and Topical Forms (MedlinePlus, NIH)

What side effects are possible with Diclomec?

Possible Side Effects and Safety Information

Diclomec (Diclofenac) is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) whose safety profile, as defined in regulatory documents (e.g., EMA, FDA), is organized by frequency and the body system affected. The most frequently reported adverse reactions, classified as Common (occurring in 1% to 10% of patients), often involve the Gastrointestinal System, including nausea, diarrhea, dyspepsia, abdominal pain, and headache.


Serious Adverse Reactions and Systemic Risks

The regulatory safety structure highlights the risk of serious adverse reactions, which can occur without warning symptoms at any time during treatment. These include potentially fatal events primarily involving two major systems:

  • Gastrointestinal Events: Life-threatening ulceration, bleeding, and perforation of the stomach or intestines.
  • Cardiovascular Thrombotic Events: Increased risk of Myocardial Infarction (MI) and Stroke. This risk may increase with the duration of use and the dose administered.

Additional serious, though rare (Very Rare, <1/10,000), reactions include severe liver reactions (hepatotoxicity/failure), acute renal failure, and severe skin conditions like Stevens-Johnson syndrome (SJS).


Safety Considerations and Restrictions

Official labels impose several safety restrictions. The medicine is contraindicated in patients with established severe heart failure, active GI bleeding, ulceration, or perforation, and post-Coronary Artery Bypass Graft (CABG) surgery pain. Older adults are noted as a population facing a higher risk for serious GI and cardiovascular events, necessitating particular attention. Furthermore, use is generally restricted during the third trimester of pregnancy due to risks to the fetus.

Overdose and Emergency Response

Overdose and When to Seek Help

A Diclomec overdose is officially documented to present with signs across multiple physiological systems. Common initial manifestations may include gastrointestinal distress, such as nausea, vomiting, stomach pain, and diarrhea. Central Nervous System (CNS) effects, including dizziness, headache, drowsiness, confusion, and ringing in the ears (tinnitus), are also recognized symptoms of toxicity listed in regulatory prescribing information.

The official profile strictly outlines the potential for severe, life-threatening outcomes, including fatal cardiovascular thrombotic events (such as myocardial infarction or stroke), gastrointestinal perforation and bleeding, and acute renal or hepatic failure. Elderly patients and individuals with pre-existing renal or hepatic impairment are explicitly noted to face increased risk for severe events during toxicity.

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdose. Individuals must contact a Poison Control Center or emergency services immediately. Management is primarily symptomatic and supportive treatment, as regulatory documents state no specific antidote is known for Diclofenac overdose. Supportive measures, such as the use of activated charcoal, may be considered in a clinical setting following a large, recent ingestion.

Therapeutic Uses of Diclomec

What Diclomec Treats: Main Uses and Benefits

Diclomec (Diclofenac) is commonly used to help manage symptoms related to pain, inflammation, and fever. It is applied across domains where additional symptomatic support is needed, assisting with easing the overall symptom burden. It is relevant for conditions that involve a combination of these challenging symptoms.

The medication is relevant for easing symptom clusters that create noticeable physiological strain, commonly associated with conditions such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Gout flares, and episodic pain like Migraine Headaches and Primary Dysmenorrhea. It is applied in clinical settings that involve acute or unstable symptom patterns, such as those following soft tissue injuries or surgical procedures, where short-term symptomatic assistance is needed.

This symptomatic focus contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations during symptomatic phases.


Quick Fact: Symptomatic Support

Symptomatic support for Joint Pain, Stiffness, and Swelling associated with inflammatory or irritative states.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

This section explains the official population eligibility and non-eligibility rules for Diclomec (Diclofenac) as documented by government regulatory bodies like the FDA and EMA.

Eligibility Scope

Classification Population or Condition
Contraindicated History of mathbfasthma or mathbfallergic reactions to aspirin or other NSAIDs
Contraindicated mathbfThird trimester of pregnancy (30 weeks gestation and later)
Contraindicated Perioperative pain in the setting of mathbfCoronary Artery Bypass Graft (CABG) surgery
Contraindicated mathbfSevere heart failure, mathbfischaemic heart disease, mathbfperipheral arterial disease, or mathbfcerebrovascular disease (Systemic forms)
Contraindicated mathbfSevere kidney or mathbfliver function impairment
Restriction Use mathbfnot established in children mathbfunder 12 years for many oral formulations
Restriction mathbfOlder adults (geriatric) require mathbfcaution due to increased risk of serious adverse events
Restriction Patients with a mathbfrecent Myocardial Infarction (MI) (Use should be mathbfavoided unless benefits outweigh risks)
Allowed mathbfAdults and mathbfadolescents (generally mathbf12 years and older for certain systemic forms)

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Diclomec based on two categories: absolute mathbfcontraindications, which prohibit use due to known severe risks (e.g., specific cardiovascular conditions or severe organ failure), and restrictions placed on populations with insufficient data or higher susceptibility to risks (e.g., pediatric and geriatric groups). Use during the mathbfthird trimester of pregnancy is mathbfcontraindicated, while use during mathbflactation is generally mathbfnot universally recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Classification (High-Level) Interacting Substances and Formal Regulatory Statements
Formal Contraindications Use is prohibited in the setting of Coronary Artery Bypass Graft (CABG) surgery. The drug is also contraindicated for patients with established Ischaemic Heart Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Class II–IV). Co-administration with other systemic NSAIDs or Aspirin is prohibited due to additive toxicity.
Pharmacokinetic (PK) Exposure Modification Co-administration with strong CYP2C9 inhibitors, such as Voriconazole, results in a significant increase in Diclofenac plasma exposure. Diclofenac may also increase the serum concentration and prolong the half-life of co-administered drugs including Digoxin, Lithium, and Methotrexate.
Pharmacodynamic (PD) Risk Enhancement Combining with Anticoagulants (e.g., Warfarin) increases the risk of bleeding. Diclofenac may diminish the therapeutic effect of medicines for blood pressure control (ACE Inhibitors/ARBs) and Diuretics.
Timing and Substance Constraints The Oral Solution formulation must be taken on an empty stomach because food reduces its effectiveness. Consumption of Alcohol or Tobacco enhances the risk of severe gastrointestinal issues.

Population-Specific Interaction Notes: The interaction between Diclofenac and ACE Inhibitors or ARBs carries a heightened risk of renal function deterioration in elderly and volume-depleted patients.

This interaction profile highlights the need for careful administration and strict adherence to label-based prohibitions to manage both drug exposure and pharmacodynamic risks.

Mechanism of Action

Diclomec's mechanism of action involves a multi-faceted approach to modulating key biological pathways associated with inflammatory and nociceptive signaling. It targets specific enzyme systems and neural signaling channels to reduce the magnitude of specific physiological responses.

Modulation of Eicosanoid Biosynthesis and Inflammatory Mediators

The primary action involves the competitive inhibition of Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 form. This process effectively modulates the Arachidonic Acid Cascade, thereby reducing the synthesis of mediators like prostaglandins (e.g., PGE2) both peripherally and centrally. This mechanism involves the modulation of prostaglandin synthesis that occurs during inflammatory processes.

Influence on Nociceptive Signaling Pathways

Beyond mediator suppression, the drug engages mechanisms that influence neural signaling itself. Diclofenac helps to stabilize nerve cell membranes by modulating Voltage-Dependent Sodium Channels and reduces the chemical sensitization of peripheral nociceptors. This pathway adjustment reduces the rate of action potential generation and transmission along the peripheral nervous system.

Regulation of Central Thermoregulatory Set-Point

The drug's mechanism extends to the Central Nervous System (CNS), where it reduces the presence of pyrogenic prostaglandins within the hypothalamus. The mechanism modulates the effect of pyrogenic mediators on the hypothalamic set-point, which influences core body temperature.

Dosage and Administration Information

The use of Diclomec (Diclofenac) is standardized around the principle of using the lowest effective dosage for the shortest duration possible. This instruction applies to all approved routes of administration, which include Oral (tablets, capsules, solution powder), Topical (gels, solutions, patches), Intravenous (IV) infusion, Intramuscular (IM) injection, and Rectal suppositories.


Administration Scope

Property Official Instruction
Route of Administration Oral, Topical, IV Infusion, IM Injection, Rectal.
Dosing Schedule (Systemic) Maximum daily dose is generally restricted to 150 mg for most systemic forms. Oral regimens range from 50 mg two to four times daily, or 100 mg extended-release once daily.
Timing in relation to meals Immediate-release forms (e.g., solution powder, liquid-filled capsules) should be taken on an empty stomach. Delayed-release tablets may be taken with or after food.
Preparation Requirements Oral solution powder must be mixed with 30 mL to 60 mL of water only and consumed immediately.
Age-Group Administration The lowest effective dosage is recommended for older adults. IV/IM use is generally not recommended for the pediatric population.
Missed-Dose Rules If a dose is missed, take it as soon as remembered, unless it is nearly time for the next dose; the missed dose should then be skipped. Do not double the dose.
Special Procedural Conditions Extended-release and delayed-release tablets must be swallowed whole; they must not be crushed, split, or chewed. Topical gel doses must be measured accurately using the provided dosing card.

Connection to the Official Use Protocol

These instructions define the protocol for administering the medicine, detailing the precise route, required dosage, and necessary preparation steps to ensure the proper delivery of the pharmaceutical product. The guidelines also establish key constraints on daily intake and duration, explicitly limiting parenteral use and requiring strict adherence to the lowest effective dose for the shortest duration consistent with symptomatic relief.

Recent Clinical Evidence

Research evidence / Overview of studies for Diclomec

Evidence for Use in Osteoarthritis (OA)

Research explored Diclomec's evaluation in studies examining symptoms of Osteoarthritis (OA), primarily relying on short- to intermediate-term Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies were used in research exploring how symptoms change over time, comparing outcomes measured for oral and topical forms in comparison to a placebo or vehicle (an inactive gel). The studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning, evaluating daily-life functioning in adults and older adults with confirmed OA in joints like the knee and hand.

Findings describe patterns observed in these studies, which focused on how patient-reported outcomes describing perceived discomfort were monitored during the short trial durations. However, long-term effects are not fully established. Data are still emerging regarding the medication's evaluation in structural progression of OA, as these were not typically the primary endpoints.


Evidence for Use in Acute Pain

Studies were conducted for Diclomec examining acute discomfort, such as pain following soft tissue injuries or certain surgical procedures, relying on Systematic Reviews and Meta-analyses that consolidate data from multiple short-term trials. Studies monitored outcomes linked to inflammatory or irritative states by measuring the proportion of participants who reported a defined level of symptomatic change over a short time interval. Studies report how symptoms were monitored in the observed populations, and research describes the patterns observed when comparing the medication to a placebo across different acute pain scenarios.

Evidence is limited regarding long-term, chronic management, as the research primarily examines temporary physiological imbalance following an acute event. The evidence quality varies across studies when it comes to managing chronic non-arthritic pain, where the observed patterns were often less consistent than those for acute, short-duration injuries.


What Remains Uncertain About Diclomec

Evidence highlights what is known—and what is still uncertain—about this medication. One key limitation is the absence of extensive long-term data; the follow-up durations were limited in many of the key efficacy trials for chronic conditions. Furthermore, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes in older patients with multiple health issues, or in pediatric populations for many uses. Research is ongoing to explore how patients reported their experience and to fill these evidence gaps.

Key Studies & References

  1. Safety review of diclofenac - Therapeutic Goods Administration (TGA) Document

Frequently Asked Questions (FAQ)

Common questions about Diclomec (FAQ)

Q: How quickly should I expect Diclomec to start working?

According to official product information, the immediate-release formulation is described as being rapidly absorbed. It is indicated to reach its maximum concentration in the blood within approximately 20 to 60 minutes after administration. This factor provides insight into the drug's onset characteristics.


Q: How long does the effect of a single dose of Diclomec typically last?

The duration of the drug's presence in the body is related to its terminal half-life. Official prescribing information describes the drug's half-life in the plasma as approximately 1 to 2 hours.


Q: Can Diclomec be taken long-term for chronic conditions?

Official documents include a warning that the risks of serious cardiovascular and gastrointestinal adverse events may increase with prolonged use and higher doses. Regulatory guidance specifies that treatment should be limited to the lowest effective dosage for the shortest duration necessary to control symptoms.


Q: Is Diclomec safe to use if I have high blood pressure?

Official warnings note that patients with conditions like uncontrolled hypertension (high blood pressure) or congestive heart failure require caution. Regulatory guidance notes that clinical monitoring is often necessary for individuals with these pre-existing conditions.


Q: What are the signs of an allergic reaction to Diclomec?

Regulatory information describes the signs of a severe allergic reaction (anaphylaxis) as potentially including difficulty breathing, swelling of the face or throat, and hives or skin rash. In the event of a suspected severe reaction, official guidance is to seek emergency assistance.


Q: Is it normal to feel drowsy after taking Diclomec?

Yes, drowsiness or somnolence is listed as an undesirable effect in the official drug product information. This means it is an effect that has been reported by patients while using the medicine.


Q: What information is available about Diclomec and breastfeeding?

Official documents indicate that diclofenac and its metabolites are excreted into human milk. Based on this finding, the use of Diclomec is generally not universally recommended in the context of breastfeeding.


Q: Can Diclomec be used to treat migraines?

Certain specific formulations of diclofenac are indicated in regulatory documents for the acute treatment of migraine attacks, with or without aura.


Q: Does Diclomec help with nerve pain?

Studies and regulatory documents describe the drug's mechanism influencing pain transmission by modulating neural mechanisms. This includes stabilizing voltage-dependent sodium channels and reducing the sensitization of peripheral pain receptors (nociceptors).


Q: Is Diclomec available without a prescription in some places?

Regulatory status can vary significantly by country. In some jurisdictions, certain lower dose oral forms and topical preparations of Diclofenac are available over-the-counter (OTC), while higher doses typically require a prescription.


Q: Are there any specific foods or drinks to avoid while taking Diclomec?

Official product information states that food significantly decreases the absorption rate of some immediate-release oral formulations. Because of this, specific immediate-release forms are typically taken on an empty stomach to optimize absorption.


Q: Does Diclomec have a risk of dependence or addiction?

No. Regulatory information does not classify Diclofenac as a controlled substance. The drug is not included in the schedules associated with physical dependence or addiction risk.


Q: Is Diclomec known to cause fluid retention or swelling?

Yes, official documents list peripheral edema (swelling or fluid retention) as a potential adverse reaction. This finding is noted within the safety profile of the medication.


Q: What is the purpose of the different dosage forms of Diclomec (e.g., tablets, gel)?

The different dosage forms are intended for different purposes and routes of administration. For instance, an oral tablet is for systemic relief of pain and inflammation, while a topical gel is indicated for localized relief, such as in certain joint pain (e.g., knee or hand osteoarthritis).


Q: Does Diclomec affect blood sugar levels?

Official adverse reaction lists include rare reports of disturbances in blood glucose levels, such as both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).


Q: Are skin rashes a common side effect of Diclomec?

Yes, rash or dermatitis is generally listed as a common adverse reaction in the official safety profile of the drug.


Q: Can Diclomec be taken with antacids?

Official interaction information advises that antacids may decrease the absorption of diclofenac.


Q: What is the evidence supporting Diclomec's use for period pain?

Certain diclofenac formulations are specifically indicated in regulatory documents for the treatment of pain associated with primary dysmenorrhea, which is the medical term for menstrual or period pain.


Q: Does Diclomec cause sun sensitivity?

Yes, photosensitivity (increased sensitivity to sunlight) is listed as an undesirable effect in official drug product information. This is noted as a factor requiring awareness regarding exposure to direct sunlight.

How should Diclomec be stored and disposed of?

How to Store and Dispose of Diclomec?

Storage and disposal requirements for Diclomec (diclofenac) are strictly defined by regulatory authorities to ensure product stability and safety.


Official Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20^circ to 25 C (68^circ to 77 F).
Protection The product must be protected from moisture and often from light. Do not freeze.
Container Keep the medicine in a tightly closed, light-resistant container.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Diclomec should not be disposed of in wastewater or household trash. Patients are instructed to ask a pharmacist or healthcare professional for the correct method to dispose of any medicine that is no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diclomec found in:

A-Z Index: